Clinical efficacy of dapagliflozin combined with QiliQiangxin Capsules in treatment of heart failure with midrange ejection fraction
Chen Yun
Lan Zhenzhen
Jiao Xueyan
Liu Luyao
Liu Xincan
Abstract：Objective To study retrospectively the clinical efficacy and safety of dapagliflozin(ainhibitor of sodium-glucose cotransporter 2,SGLT2)combined with QiliQiangxin Capsules in patients with heart failure with midrange ejection fraction(40%～49%,HFmrEF).Methods The patients with HFmrEF and blood stasis pattern with yang-qi deficiency(n=70)were chosen from Heart Center of the First Affiliated Hospital of Henan University of Chinese Medicine from Aug.2022 to Sept.2023.The patients were divided,according to different therapies,into control group treated with routine therapy and dapagliflozin and study group treated with dapagliflozin combined with QiliQiangxin Capsules(each n=35)for more than 4 weeks.The indexes of NYHA grades,6-minute walk test(6MWT),scores of Minnesota Living with Heart Failure Questionnaire(MLHFQ),heart rate(HR),indexes related to heart function by echocardiogram[left ventricular end-diastolic diameter(LVEDd),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP)]and re-hospitalization rate within 30 d were compared between 2 groups,and given statistical analysis.Results Compared with control group,NYHA grades decreased significantly(P＜0.05),MLHFQ scores decreased significantly(P＜0.01)and 6MWT increased significantly(P＜0.01)in study group.The total effective rate was significantly higher(P＜0.01),NT-proBNP level was lower(P＜0.01),LVIDd and LVEF were significantly lower(P＜0.01,P＜0.01)in study group than those in control group after treatment.The mean basic heart rate decreased in varying degrees in 2 groups after treatment compared with before(P＜0.05).The improvement of HR indexes was more significant in study group compared with control group after treatment(P＜0.01).There were higher safety and tolerance in 2 groups during follow-up and medication period,and difference in 30-d re-hospitalization rate and re-consultation had no statistical significance between 2 groups.Conclusion Dapagliflozin combined with QiliQiangxin Capsules can significantly relieve symptoms and improve heart function in HFmrEF patients with blood stasis pattern with yang-qi deficiency,which can be taken a clinical reference for the choice of therapeutical scheme in HFmrEF patients.
Keywords：Heart failure with midrange ejection fractionDapagliflozinQiliQiangxin Capsules
Publication Date：2024-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 547-551 )